MOLECULAR PARTNERS AG (MOLN): Price and Financial Metrics


MOLECULAR PARTNERS AG (MOLN): $6.58

-0.15 (-2.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MOLN to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MOLN Stock Price Chart Interactive Chart >

Price chart for MOLN

MOLN Price/Volume Stats

Current price $6.58 52-week high $29.06
Prev. close $6.73 52-week low $5.50
Day low $6.50 Volume 4,100
Day high $6.67 Avg. volume 1,924
50-day MA $6.68 Dividend yield N/A
200-day MA $7.50 Market Cap 237.18M

MOLECULAR PARTNERS AG (MOLN) Company Bio


Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. It also develops its products through its brand known as DARPins, which targets specific and potent monoclonal antibodies that offers potential to address existing limitations of antibody drugs. The company products include Abicipar, MP0250/MP0274 and Clinical Trials.


MOLN Latest News Stream


Event/Time News Detail
Loading, please wait...

MOLN Latest Social Stream


Loading social stream, please wait...

View Full MOLN Social Stream

Latest MOLN News From Around the Web

Below are the latest news stories about MOLECULAR PARTNERS AG that investors may wish to consider to help them evaluate MOLN as an investment opportunity.

Molecular Partners Initiates Clinical Study of Trispecific Candidate MP0533 for the Treatment of Acute Myeloid Leukemia

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 16, 2023 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, announced today that the first patient has been treated in a Phase 1 first-in-human study evaluating the safety, tolerability, and efficacy of MP0533, the company’s candidate for acute myeloid leukemia (AML). MP0533 is designed to focus an immune attack against AML in a new way that preferentially spares healthy cells, which has been a historic challenge for CD3-targeting therapeutics.

GlobeNewswire | January 16, 2023

Molecular Partners starts early-stage study of blood cancer drug MP0533

Molecular Partners (MOLN) said the first patient was treated in a phase 1 trial of its blood cancer drug MP0533.The study will enroll patients with relapsed/refractory acute…

Seeking Alpha | January 16, 2023

Hedge funds own 28% of Molecular Partners AG (VTX:MOLN) shares but individual investors control 41% of the company

A look at the shareholders of Molecular Partners AG ( VTX:MOLN ) can tell us which group is most powerful. With 41...

Yahoo | January 12, 2023

Molecular Partners Provides Updates at 41st Annual JPM Healthcare Conference

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 08, 2023 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR : Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced several developments in its infectious disease and oncology portfolios. These include: DARPin Radioligand Therapy platform progressing well. Disclosure of the tumor-associated protein Delta-

Yahoo | January 8, 2023

Molecular Partners to Present at 41st Annual JP Morgan Healthcare Conference and Swiss Investor Conferences

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 30, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the 41st annual JP Morgan Healthcare Conference in San Francisco, CA. In addition, members of Molecular Partners management will participate in several upcom

Yahoo | December 30, 2022

Read More 'MOLN' Stories Here

MOLN Price Returns

1-mo 5.28%
3-mo 4.82%
6-mo 6.30%
1-year -76.47%
3-year N/A
5-year N/A
YTD 0.46%
2022 -65.85%
2021 N/A
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 2.0469 seconds.